Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-22-032089
Filing Date
2022-06-10
Accepted
2022-06-09 20:40:12
Documents
68
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.1 TO FORM 10-K f10k2021a1_rasnatherap.htm   iXBRL 10-K/A 1255562
2 CERTIFICATIONS f10k2021a1ex31-1_rasnatherap.htm EX-31.1 11198
3 CERTIFICATIONS f10k2021a1ex31-2_rasnatherap.htm EX-31.2 11226
4 CERTIFICATIONS f10k2021a1ex32-1_rasnatherap.htm EX-32.1 3611
5 CERTIFICATIONS f10k2021a1ex32-2_rasnatherap.htm EX-32.2 3630
6 GRAPHIC image_001.jpg GRAPHIC 58312
  Complete submission text file 0001213900-22-032089.txt   5521038

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE rasp-20210930.xsd EX-101.SCH 47387
8 XBRL CALCULATION FILE rasp-20210930_cal.xml EX-101.CAL 24360
9 XBRL DEFINITION FILE rasp-20210930_def.xml EX-101.DEF 226056
10 XBRL LABEL FILE rasp-20210930_lab.xml EX-101.LAB 445567
11 XBRL PRESENTATION FILE rasp-20210930_pre.xml EX-101.PRE 243157
62 EXTRACTED XBRL INSTANCE DOCUMENT f10k2021a1_rasnatherap_htm.xml XML 580638
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

EIN.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-K/A | Act: 34 | File No.: 333-191083 | Film No.: 221007413
SIC: 2834 Pharmaceutical Preparations